GlassScriptPhysician profile
Paul M Meiners
NPI 1588044630
$2,690.04
in general payments reported to CMS, 2019-2025
24 companies · $451 in 2025
The $451 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $122 · 2021: $282 · 2022: $228 · 2023: $942 · 2024: $565 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $554.13 | 2019-2025 | Arexvy, Bexsero, Shingrix |
| Novo Nordisk INC | $335.54 | 2020-2025 | Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $225.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $197.79 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $195.37 | 2021-2025 | Otezla, Repatha, Repatha |
| Genzyme Corporation | $150.12 | 2025 | |
| Abbvie INC. | $145.89 | 2023-2024 | |
| Exact Sciences Corporation | $143.69 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $132.21 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $126.79 | 2021-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $80.02 | 2023-2024 | Qelbree, Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $79.45 | 2025 | |
| Pfizer INC. | $54.26 | 2021-2025 | |
| Corium, LLC | $52.32 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $39.73 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $23.82 | 2025 | Ohtuvayre |
| Ultragenyx Pharmaceutical INC. | $22.52 | 2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $21.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.39 | 2021 | |
| Ironshore Pharmaceuticals INC. | $21.17 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.37 | 2023 | |
| Hologic Sales and Service, LLC | $17.31 | 2023 | Thinprep 2000 Processor |
| Chiesi USA, INC. | $15.35 | 2024 | Elfabrio |
| Astellas Pharma US INC | $15.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Meiners listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.